alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Corporate Authors:
      RISC Study Group
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: Electronic Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Insulin Resistance*; Diabetes Mellitus/*metabolism ; Glucose Intolerance/*metabolism ; Hydroxybutyrates/*metabolism; Adult ; Biomarkers/metabolism ; Blood Glucose/metabolism ; Demography ; Diabetes Mellitus/blood ; Female ; Humans ; Male ; Metabolome ; Middle Aged ; Models, Biological ; Receptor, Insulin/metabolism
    • Abstract:
      Background: Insulin resistance is a risk factor for type 2 diabetes and cardiovascular disease progression. Current diagnostic tests, such as glycemic indicators, have limitations in the early detection of insulin resistant individuals. We searched for novel biomarkers identifying these at-risk subjects.
      Methods: Using mass spectrometry, non-targeted biochemical profiling was conducted in a cohort of 399 nondiabetic subjects representing a broad spectrum of insulin sensitivity and glucose tolerance (based on the hyperinsulinemic euglycemic clamp and oral glucose tolerance testing, respectively).
      Results: Random forest statistical analysis selected alpha-hydroxybutyrate (alpha-HB) as the top-ranked biochemical for separating insulin resistant (lower third of the clamp-derived M(FFM) = 33 [12] micromol x min(-1) x kg(FFM) (-1), median [interquartile range], n = 140) from insulin sensitive subjects (M(FFM) = 66 [23] micromol x min(-1) x kg(FFM) (-1)) with a 76% accuracy. By targeted isotope dilution assay, plasma alpha-HB concentrations were reciprocally related to M(FFM); and by partition analysis, an alpha-HB value of 5 microg/ml was found to best separate insulin resistant from insulin sensitive subjects. alpha-HB also separated subjects with normal glucose tolerance from those with impaired fasting glycemia or impaired glucose tolerance independently of, and in an additive fashion to, insulin resistance. These associations were also independent of sex, age and BMI. Other metabolites from this global analysis that significantly correlated to insulin sensitivity included certain organic acid, amino acid, lysophospholipid, acylcarnitine and fatty acid species. Several metabolites are intermediates related to alpha-HB metabolism and biosynthesis.
      Conclusions: alpha-hydroxybutyrate is an early marker for both insulin resistance and impaired glucose regulation. The underlying biochemical mechanisms may involve increased lipid oxidation and oxidative stress.
    • References:
      Diabetes. 1974 Aug;23(8):674-8. (PMID: 4852112)
      Circulation. 1996 May 15;93(10):1809-17. (PMID: 8635260)
      Curr Diab Rep. 2009 Jun;9(3):193-9. (PMID: 19490820)
      Clin Chim Acta. 1975 Jan 6;58(1):23-32. (PMID: 164303)
      Diabetes Care. 1991 Mar;14(3):173-94. (PMID: 2044434)
      Biochim Biophys Acta. 1986 Aug 29;888(1):18-24. (PMID: 3741887)
      Altern Med Rev. 2008 Sep;13(3):205-15. (PMID: 18950247)
      Endocrinology. 2008 Jul;149(7):3478-89. (PMID: 18372322)
      Diabetes. 2009 Apr;58(4):773-95. (PMID: 19336687)
      N Engl J Med. 2006 Jun 15;354(24):2552-63. (PMID: 16775236)
      Pharmacogenomics. 2008 Apr;9(4):383-97. (PMID: 18384253)
      J Clin Endocrinol Metab. 1998 Aug;83(8):2773-6. (PMID: 9709945)
      Clin Invest Med. 1995 Aug;18(4):231-9. (PMID: 8549007)
      J Clin Invest. 1970 Dec;49(12):2151-60. (PMID: 5480843)
      Circulation. 1997 Aug 5;96(3):849-55. (PMID: 9264492)
      Ann N Y Acad Sci. 1999 Nov 18;892:45-57. (PMID: 10842651)
      Diabetes Care. 2008 Jul;31(7):1433-8. (PMID: 18594063)
      Scand J Clin Lab Invest. 1975 May;35(3):259-66. (PMID: 168632)
      Nature. 2009 Feb 12;457(7231):910-4. (PMID: 19212411)
      Ann Intern Med. 1990 Dec 15;113(12):909-15. (PMID: 2240915)
      Diabetes Care. 1992 Jan;15(1):1-7. (PMID: 1737525)
      Diabetes. 2007 Jun;56(6):1489-501. (PMID: 17526912)
      Braz J Med Biol Res. 2001 May;34(5):627-31. (PMID: 11323749)
      Physiol Genomics. 2007 Apr 24;29(2):99-108. (PMID: 17190852)
      Anal Chem. 2009 Aug 15;81(16):6656-67. (PMID: 19624122)
      Am J Med. 1983 Nov 30;75(5B):85-93. (PMID: 6369971)
      Clin Chim Acta. 1985 Jan 30;145(2):173-82. (PMID: 3918815)
      J Clin Endocrinol Metab. 2007 Aug;92(8):2885-92. (PMID: 17504904)
      N Engl J Med. 2008 Nov 20;359(21):2220-32. (PMID: 19020324)
      Cell Metab. 2009 Apr;9(4):311-26. (PMID: 19356713)
      Annu Rev Nutr. 2007;27:293-310. (PMID: 17666010)
      Am J Physiol Endocrinol Metab. 2008 Jan;294(1):E15-26. (PMID: 17957034)
      Adv Metab Disord. 1978;9:313-31. (PMID: 417568)
      Toxicol Pathol. 2009 Apr;37(3):280-92. (PMID: 19380839)
      Diabetologia. 2004 Mar;47(3):566-570. (PMID: 14968294)
      Diabetes Care. 2007 Jan;30(1):89-94. (PMID: 17192339)
      Nature. 1960 Dec 24;188:1110-1. (PMID: 13743238)
      Clin Chim Acta. 1973 Oct 12;48(2):213-9. (PMID: 4202348)
    • Accession Number:
      0 (Biomarkers)
      0 (Blood Glucose)
      0 (Hydroxybutyrates)
      EC 2.7.10.1 (Receptor, Insulin)
      O0ADR0I4H5 (2-hydroxybutyric acid)
    • Publication Date:
      Date Created: 20100608 Date Completed: 20100907 Latest Revision: 20240315
    • Publication Date:
      20240315
    • Accession Number:
      PMC2878333
    • Accession Number:
      10.1371/journal.pone.0010883
    • Accession Number:
      20526369